Dr. Reddy's Laboratories Limited Book Value 2011-2026 | RDY

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Dr. Reddy's Laboratories Limited

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
173 B	155 B	-	-	1.91 B	1.94 B	1.79 B	1.51 B	1.34 B	1.13 B	1.03 B

All numbers in INR currency

Indicator range from annual reports

Maximum	Minimum	Average
173 B	1.03 B	37.6 B

Quarterly Book Value Dr. Reddy's Laboratories Limited

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	191 B	-	-	-	173 B	-	-	-	155 B	-	-	-	140 B	-	-	-	126 B	-	-	-	124 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in INR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
191 B	124 B	152 B

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
BioNTech SE BNTX	19.2 B	$ 91.28	0.11 %	$ 27.2 B	Germany
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Akari Therapeutics, Plc AKTX	28.3 M	$ 3.54	-20.81 %	$ 238 B	Britain
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	169 M	-	-	$ 28.6 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Alnylam Pharmaceuticals ALNY	789 M	$ 330.34	3.6 %	$ 43.3 B	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	16.9 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	78.8 M	-	4.14 %	$ 49.1 M	USA
Evogene Ltd. EVGN	14.8 M	$ 0.79	1.22 %	$ 27.9 M	Israel
Atreca BCEL	78.4 M	-	-11.76 %	$ 5.79 M	USA
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
argenx SE ARGX	7.32 B	$ 748.25	0.25 %	$ 25 B	Niderland
Завод ДИОД DIOD	-243 M	-	-	-	Russia
Фармсинтез LIFE	29.8 B	-	-	-	Russia
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Aptorum Group Limited APM	11.8 M	$ 0.89	-4.33 %	$ 4.85 M	China
Applied Therapeutics APLT	-17.1 M	-	-	$ 8.42 M	USA
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Teligent, Inc. TLGT	5.17 B	-	-13.85 %	$ 16.1 M	USA
AbbVie ABBV	134 B	$ 206.69	-1.01 %	$ 366 B	USA
Aquestive Therapeutics AQST	-33.7 M	$ 4.09	-0.97 %	$ 437 M	USA
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Viela Bio, Inc. VIE	424 M	-	-	$ 2.91 B	USA
AbCellera Biologics ABCL	967 M	$ 3.39	-3.69 %	$ 1.01 B	Canada
Arcturus Therapeutics Holdings ARCT	214 M	$ 8.22	2.37 %	$ 225 M	Israel
Ardelyx ARDX	167 M	$ 5.97	0.51 %	$ 1.44 B	USA
Genmab A/S GMAB	19.1 B	$ 27.75	0.91 %	$ 17.6 B	Danmark
Cerevel Therapeutics Holdings CERE	674 M	-	-	$ 7.29 B	USA
Grifols, S.A. GRFS	8.61 B	$ 8.23	-0.12 %	$ 6.83 B	Spain
Akebia Therapeutics AKBA	32.6 M	$ 1.32	-4.35 %	$ 339 M	USA